Skip to content

Nuvation Bio NUVB Deferred Tax Liabilities, Gross

Deferred Tax Liabilities, Gross at other companies

BillionToOne, Inc.
 logo
BillionToOne, Inc. BLLN

Other financials

Income statement

See full
Revenue$83.2M+2,599%
Gross profit$9.8M+1,340%
Operating income$3.9M+107%
Net income$5.4M+110%
EPS (diluted)$0.01+106%

Balance sheet

See full
Cash & equivalents$125.4M+161%
Total debt$57.2M+401%
Total equity$319.6M-23.8%
Total assets$610.2M+23.9%

Cash flow

See full
Operating cash flow$5.1M+112%
CapEx$48.0K-33.3%
Free cash flow$5.0M+112%

Valuation

See full
Market cap$2.25B+150%

Profitability

See full
Gross margin54.3%+39.5pp
Operating margin-105%-52.0pp
Net margin-102.1%-50.6pp
FCF margin-93.5%-45.2pp

Returns & leverage

See full
Return on equity-39.5%-15.8pp
Debt / equity0.2×+0.2×
Current ratio7.4×-1.6×

Where this comes from

Reported directly by Nuvation Bio in its filing.

Tagged under the XBRL concept us-gaap:DeferredIncomeTaxLiabilities.

The official record: Nuvation Bio’s 10-K, filed March 2, 2026, on SEC EDGAR. View the filing →

Ask your AI about Nuvation Bio's deferred tax liabilities, gross.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Nuvation Bio's deferred tax liabilities, gross?
Nuvation Bio (NUVB) reported deferred tax liabilities, gross of $811K in Q4 2025.
How has Nuvation Bio's deferred tax liabilities, gross changed year-over-year?
Nuvation Bio's deferred tax liabilities, gross decreased by 81.8% year-over-year, from $4.44M to $811K.
What is the long-term trend for Nuvation Bio's deferred tax liabilities, gross?
Over 5 years (2020 to 2025), Nuvation Bio's deferred tax liabilities, gross has grown at a 11.3% compound annual growth rate (CAGR), from $475K to $811K.